Rigel Pharmaceuticals (RIGL) EBT (2010 - 2026)

Rigel Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, EBT rose 1.27% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $122.0 million (up 219.94% YoY), while the FY2025 annual figure was $121.8 million, up 563.33% from the prior year.
• EBT was $11.7 million for Q1 2026 at Rigel Pharmaceuticals, down from $22.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $60.0 million in Q2 2025 to a low of -$27.4 million in Q1 2022.
• Historically, EBT has averaged $4.0 million across 5 years, with a median of $737000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT plunged 166.5% in 2022, then soared 5923.5% in 2025.
• A 5-year view of EBT shows it stood at $1.4 million in 2022, then slumped by 47.39% to $737000.0 in 2023, then soared by 1965.4% to $15.2 million in 2024, then soared by 49.22% to $22.7 million in 2025, then sank by 48.68% to $11.7 million in 2026.
• The last three EBT figures came in at $11.7 million (Q1 2026), $22.7 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.